Carillon Tower Advisers, an investment management company, released its fourth-quarter 2025 investor letter for the “Carillon ...
Natera, Inc.'s revenue growth remains strong, driven by rapid adoption of Signatera, now covered by Medicare, which should provide recurring revenue and some competitive advantage. Litigation risks ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has received written confirmation from the Centers for Medicare & ...
Genetic testing company Natera (NASDAQ:NTRA). reported Q1 CY2025 results , with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue guidance of $1.98 billion at the midpoint ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the results of a study led by Stanford University School of Medicine for the evaluation of ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the submission of its premarket approval (PMA) to the U.S. Food and Drug Administration (FDA) for ...
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive Signatera Genome assay is now broadly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results